Could a cancer drug fight the wasting away seen in advanced lung cancer?

NCT ID NCT04906746

Ongoing Symptom relief Sponsor: Tu Dan Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This pilot study tests the drug ruxolitinib in people with advanced non-small cell lung cancer who are experiencing cancer cachexia—unintended weight loss and muscle wasting. The main goal is to check for side effects and see how the drug affects body signals related to appetite and muscle breakdown. Ten participants receive gradually increasing doses of ruxolitinib, and researchers measure changes in blood, fat, and muscle tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib
What this could lead to: If successful, this could point toward a treatment for cancer-related weight loss and muscle wasting, improving quality of life.
What could go wrong: This is a very early, small pilot study with only 10 participants, so results may not apply broadly. Ruxolitinib can cause side effects like infections and blood cell changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CACHEXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anorexia Cachexia lung neoplasm muscular atrophy non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CACHEXIA STAGE IV NON-SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Locations

UT Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.